BioAtla Investor Presentation Deck

Focused Pipeline with Broad Applicability of Differentiated CAB Assets Designed to Deliver Near-term value CAB-ADCS CAB-I/O CAB- Bispecific TCE CAB bicatla CAB Program BA3011 Mecbotamab Vedotin BA3021 Ozuriftamab Vedotin BA3071 Evalstotug BA3182 Target AXL ROR2 CTLA-4 EpCAM x CD3 Additional programs Various Indications UPS NSCLC Melanoma SCCHN Melanoma NSCLC Carcinomas Multiple tumor types Multiple tumor types IND Enabling Pre-Clinical Phase 1 Clinical IND, investigational new drug; UPS, Undifferentiated Pleomorphic Sarcoma; NSCLC, Non-small Cell Lung Cancer; SCCHN, Squamous Cell Carcinoma of the Head and Neck Phase 2 Clinical BioAtla| Overview 8

View entire presentation